Showing 7501-7510 of 8824 results for "".
- Nivolumab Shows Promise in Advanced SCChttps://practicaldermatology.com/news/nivolumab-shows-promise-in-advanced-scc/2461399/Numerous studies have shown that immune checkpoint inhibitors can boost the immune system’s response against various cancers, and now, a phase II clinical trial has demonstrated that patients with advanced cutaneous squamous cell carcinoma can benefit from nivolumab. The research is publish
- Game Changer: Incyte’s Ruxolitinib Reverses Vitiligohttps://practicaldermatology.com/news/game-changer-incytes-ruxolitinib-reverses-vitiligo/2461392/Topical Ruxolitinib is highly effective for skin re-pigmentation in vitiligo, according to Phase III clinical trial results published in The New England Journal of Medicine. The study showed better than 75 percent improvement on face and 50 percent improvement on body fo
- Dr. Ida Orengo Named Chair of Department of Dermatology at Baylor College of Medicinehttps://practicaldermatology.com/news/dr-ida-orengo-named-chair-of-department-of-dermatology-at-baylor-college-of-medicine/2461384/Dr. Ida Orengo has been named chair of the Department of Dermatology at Baylor College of Medicine by the College’s Board of Trustees. Her appointment is effective Oct. 17. Dr. Ore
- ASDSA's 2022 Top Advocates Recognizedhttps://practicaldermatology.com/news/asdsas-2022-top-advocates-recognized/2461381/Meet the American Society for Dermatologic Surgery Association (ASDSA) honorees from the fourth annual Top Advocate program Honorees are chosen based on their contribution to various advocacy efforts throughout the year and demonstrated commitment to patient safety in the field of derma
- Industry Vet Curtis Cluff Named President and CFO of BioPhotas Inc.https://practicaldermatology.com/news/industry-vet-curtis-cluff-named-president-and-cfo-of-biophotas-inc/2461378/Curtis Cluff is the new President and Chief Financial Officer BioPhotas Inc., manufacturers of the Celluma series of light therapy devices. In this newly created role, Mr. Cluff will report to Patrick Johnson, Chief Executive Officer and inventor of the Celluma. &quo
- Octagam 10% Performs Well in Adults with Dermatomyositishttps://practicaldermatology.com/news/octagam-10-performs-well-in-adults-with-dermatomyositis/2461376/Octapharma’s Octagam 10% [Immune Globulin Intravenous (Human)] is efficacious and well-tolerated in adults with dermatomyositis, ac
- National Physician Assistant Week Celebrates Work of PAshttps://practicaldermatology.com/news/national-physician-assistant-week-celebrates-work-of-pas/2461373/The American Academy of Physician Associates (AAPA) is celebrating National Physician Assistant Week October 6-12 to recognize the PA profession and its contributions to the nation’s health. This PA Week, the AAPA wants to spread the word: PAs Go Beyond! Do you know a PA who goes beyond? Th
- Business News: Incyte Buys Startup Villarishttps://practicaldermatology.com/news/business-news-incyte-buys-startup-villaris/2461370/Incyte will pay $70 million upfront to buy Villaris Therapeutics, a startup working on an experimental drug for vitiligo. Villaris’ lead asset, auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody (mAb), is expected to enter clinical development in 2023. Villaris&
- New Research: Ticks Weaken Skin's Immune Responsehttps://practicaldermatology.com/news/new-research-ticks-weaken-skins-immune-response/2461364/Tick saliva inhibits the skin's defense function, thereby increasing the risk of diseases such as tick-borne encephalitis (TBE) or Lyme disease, according to new research in the Journal of Clinical Investigation. The re
- FDA Clears CellFX System for the Treatment of SHhttps://practicaldermatology.com/news/fda-clears-cellfx-system-for-the-treatment-of-sh/2461358/The U.S. Food and Drug Administration (FDA) granted Pulse Bioscience’s CellFX System (FDA) 510(k)marketing clearance for the treatment of sebaceous hyperplasia in patients with Fitzpatrick skin types I-II. This specific indication clearance enhances the CellFX